Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.
Stephen T. Oh, MD, PhD, co-chief, Division of Hematology, associate professor, Department of Medicine, Hematology Division, associate professor, Department of Pathology and Immunology, Washington University School of Medicine in St. Louis, discusses the benefits of pacritinib (Vonjo) in patients with myelofibrosis.
The primary analysis of the phase 3 PERSIST-2 study (NCT02055781) showed that patients treated with pacritinib were more likely to experience clinical improvement in hemoglobin compared with those who received best available therapy (BAT), Oh says. Although the primary analysis did not report the degrees of anemia response and transfusion independence, updated findings from this trial included transfusion independence rates in patients who received the 200 mg FDA-approved dose of pacritinib vs those treated with BAT, Oh explains.
In this analysis, pacritinib elicited a superior transfusion independence rate over BAT, at 24% vs 5% per SIMPLIFY criteria and 37% vs 7% per Gale criteria, Oh concludes.
Funding supported by CTI Biopharma. Content independently developed by OncLive